Takeda Expands Abroad While Finding Its Way In Its Home Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda announces cross-licensing deals with Dainippon Sumitomo in a rights swap in Europe and Japan that involves ceftaroline and lurasidone.
You may also be interested in...
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.
Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions
TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture